Evolus ROA 2016-2018 | EOLS
Current and historical return on assets (ROA) values for Evolus (EOLS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Evolus ROA for the three months ending September 30, 2018 was -14.93%.
|Evolus ROA - Return on Assets Historical Data
||TTM Net Income
||Return on Assets
||Medical Products Manufacturing
Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.